Platelet Patents (Class 424/532)
  • Patent number: 10383833
    Abstract: The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: August 20, 2019
    Assignee: Milanapharm LLC
    Inventors: Hemant H Alur, James A H Harwick
  • Patent number: 10358627
    Abstract: Synthetic storage media are disclosed for use in the processing and the storing of platelets. The storage media includes a platelet storage solution and less than 20 percent plasma to preserve platelet function after at least 7 days of storage.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: July 23, 2019
    Assignee: FENWAL, INC.
    Inventors: Veronique Mayaudon, Jean-Marc Payrat
  • Patent number: 9867852
    Abstract: The invention relates to a viral inactivated biological liquid or dry mixture and to its preparation. Principally, the invention relates, but is not limited, to a mixture derived from a platelet source.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: January 16, 2018
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Lior Weissman, Itai Podoler, Israel Nur, Tamara Byk-Tennenbaum
  • Patent number: 9759730
    Abstract: The invention lies in the area of platelet function diagnostics and relates to a method for the determination of platelet function under flow conditions as well as a device for the implementation of this method. The method is particularly suitable for the determination of the effect of clopidogrel and of other P2Y(12) antagonists with antithrombotic activity as well as the determination of P2Y(1) antagonists with antithrombotic activity.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: September 12, 2017
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventor: Andreas Rechner
  • Patent number: 9609861
    Abstract: The present invention relates to a platelet additive solution (PAS) having an amount of one or more ?-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: April 4, 2017
    Assignees: Velico Medical Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Qiyong Peter Liu, Karin Hoffmeister, Robert Sackstein
  • Patent number: 9506938
    Abstract: A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.
    Type: Grant
    Filed: May 1, 2008
    Date of Patent: November 29, 2016
    Assignee: ACCUMETRICS, INC.
    Inventors: Barry Coller, Dennis Durbin
  • Patent number: 9173906
    Abstract: A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vile, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, TGF?, and TNF?, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second vial.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: November 3, 2015
    Assignee: Smith & Nephew, Inc.
    Inventors: Eric Rolland, Thomas Hunziker, Beatrice Chevallay, Christopher Rinsch
  • Patent number: 9168281
    Abstract: Provided herein are compositions for treating wounds, method of making and using the system thereof. The system or kit for treating a wound includes a first composition having cetylpyridinium chloride, Aloe vera, and ascorbic acid for sanitizing a wound. The system or kit includes a second composition having concentrated platelet-rich plasma and a hypertonic saline solution for activating granulation of the wound. The system or kit includes a third composition having Aloe vera, ascorbic acid, vitamin A, vitamin E and immunoglobulins for initiating re-epithelialization of the wound.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: October 27, 2015
    Inventor: Charles E. Worden, Sr.
  • Patent number: 9095704
    Abstract: A method of mitigating the effect of bodily pathogens including providing a light applicator including a housing, a power supply, and at least one light source wherein the light source is configured to emit light in the ultraviolet range when energized by the power supply, and directing the applicator toward a bodily orifice so as to directly irradiate the orifice for a period of time.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: August 4, 2015
    Assignee: UV Technologies, LLC
    Inventor: Kevin McGuire
  • Patent number: 9080141
    Abstract: The present invention is directed to a device for the growth of new bone or bone-like tissue under in vitro cell culture conditions.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: July 14, 2015
    Assignee: LifeNet Health
    Inventors: Lloyd Wolfinbarger, Xiaofei Qin
  • Patent number: 9034646
    Abstract: The invention concerns human platelet extracts rich in growth factors (PGF) for wound healing and stem cell expansion. Accordingly the subject invention relates to a virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF, which is preferably enriched in TGF, IGF and EGF-rich. The present invention further concerns a method for obtaining a platelet lysate comprising the steps of contacting a starting platelet concentrate with a solvent and/or a detergent, incubating the starting platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C., optionally removing the solvent and/or the detergent by oil extraction and obtaining an aqueous protein phase, and incubating the solvent and/or detergent-treated platelet concentrate or the aqueous protein phase with charcoal.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: May 19, 2015
    Assignee: ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD.
    Inventors: Thierry Burnouf, Cheng-Yao Su
  • Publication number: 20140377336
    Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
    Type: Application
    Filed: January 22, 2013
    Publication date: December 25, 2014
    Inventors: Dennis Brown, Jeffrey Bacha, Sandra Dunn
  • Publication number: 20140335195
    Abstract: The invention concerns a pharmaceutical composition comprising a platelet lysate and its use to treat a wound, an anal fissure, vaginal atrophy or a wrinkle.
    Type: Application
    Filed: November 23, 2012
    Publication date: November 13, 2014
    Applicant: CELL THERAPY LIMITED
    Inventors: Thomas Averell Houze, Martin John Evans, Ajan Reginald, Ina Laura Pieper
  • Patent number: 8871199
    Abstract: Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: October 28, 2014
    Assignee: Regenerative Sciences, LLC
    Inventor: Christopher J. Centeno
  • Publication number: 20140287014
    Abstract: This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry, said slurry comprising a plurality of natural or synthetic polymer fibers and at least one suspension fluid, wherein the polymer fibers are substantially evenly dispersed and randomly oriented throughout the volume of the suspension fluid; applying a force, e.g., centrifugal, to said vessel containing said slurry, whereupon said force serves to cause said polymer fibers to migrate through the suspension fluid and amass at a furthest extent of the vessel, forming a polymer material, with said polymer material comprising polymer fibers of sufficient length and sufficiently viscous, interlaced, or interlocked to retard dissociation of said polymer fibers.
    Type: Application
    Filed: January 20, 2014
    Publication date: September 25, 2014
    Inventors: Timothy A. Ringeisen, William Christopher Wattengel
  • Patent number: 8821858
    Abstract: This invention relates to an improved Lyophilized platelet rich plasma used to make a platelet gel wound healant, and methods of preparation and use thereof for healing wounds are disclosed. The improved wound healant comprises therapeutically effective amounts of activated growth factors, platelet ghost, plasma (know as the plasma back bone), white blood cells with optional none, one or more additional anti-oxidant such as vitamin A and/or C and/or E, and/or none one or more antibiotics and/or GHK-Cu (produced by ProCyte Inc.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: September 2, 2014
    Assignee: GW IP, LLC
    Inventors: James Bennie Gandy, Mackie J. Walker, Jr.
  • Publication number: 20140186455
    Abstract: An implant for promoting accelerated wound healing. The implant comprises a non-flocculating fiber material, admixed with a settable fluid. The fiber component typically will have short fiber lengths, so as to avoid forming entangled masses or clumps when mixed with a fluid. In an embodiment, the fiber material is native collagen fibers and the settable fluid is an isolated blood fraction, such as platelet rich plasma and platelet poor plasma. The native collagen fiber retaining the native crosslinks of the source tissue and providing an architectural and structural scaffolding for advancing cellular infiltration. The wound healing implant will accelerate the bodies healing process, to provide better healing and less scar tissue of the wound site.
    Type: Application
    Filed: December 31, 2012
    Publication date: July 3, 2014
    Inventors: Gino Bradica, Ryan Saska, Christopher DiJiacomo, Timothy A. Ringeisen
  • Patent number: 8734854
    Abstract: A sub-atmospheric, negative pressure is applied to a growth factor starting material, such as whole blood, to release growth factors and plasma in a non-destructive medium. The released growth factors having a weight of about 70-76 kDaltons are applied in either a filtered or unfiltered state to a wound to promote healing of the wound. The released growth factors are applied topically to the area of a surface wound to effect healing. The released growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by conventional lyophilization. Then at a later date, the freeze dried product is reconstituted by normal saline for treatment of a patient's wound or for use in a surgical procedure.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: May 27, 2014
    Inventors: James B. Gandy, Robert J. Brandt, Ryan N. Brandt, Clark Galen, Joseph F. Greco, John Kiwczak
  • Publication number: 20140127314
    Abstract: In certain embodiments, this disclosure describes compositions comprising platelet lysates depleted of fibrinogen. In a further embodiment, the composition further comprises a cell culture medium component. This disclosure also provides a method for preparing the composition, comprising the steps of (a) lysing platelets providing a lysate; (b) removing cell debris; and (c) depleting fibrinogen by forming a removable mass by adding a metal salt such as calcium chloride. Furthermore, the disclosure also describes the product produced using said method.
    Type: Application
    Filed: June 26, 2012
    Publication date: May 8, 2014
    Applicants: CHILDREN'S HEATLHCARE OF ATLANTA, INC., EMORY UNIVERSITY
    Inventors: Ian B. Copland, Jacques Galipeau
  • Publication number: 20140056989
    Abstract: The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.
    Type: Application
    Filed: November 5, 2013
    Publication date: February 27, 2014
    Applicant: Omrix Biopharmaceuticals Ltd.
    Inventors: Lior Weissman, Nina Raver-Shapira, Israel Nur, Oleg Belyaev
  • Publication number: 20140037750
    Abstract: Automated systems and methods for providing platelet concentrates and synthetic storage media with reduced residual plasma volumes are disclosed. The disclosed systems and methods reduce the residual volume of plasma in platelet concentrate to obtain a platelet product having a volume of plasma that is approximately 5% or less of the total platelet product volume. The disclosed systems and methods also reduce the residual volume of plasma in platelet concentrate to obtain a washed platelet product, wherein the volume of plasma in the washed platelet product is approximately 1% or less of the total washed platelet product volume. Storage media for platelets including less than approximately 10% plasma are also disclosed.
    Type: Application
    Filed: April 6, 2012
    Publication date: February 6, 2014
    Applicant: Fenwal, Inc.
    Inventors: Katherine Radwanski, Kyungyoon Min
  • Patent number: 8603541
    Abstract: The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: December 10, 2013
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Lior Weissman, Nina Raver-Shapira, Israel Nur, Oleg Belyaev
  • Patent number: 8603821
    Abstract: A method for preparing serum and a serum preparation apparatus is provided that can give a large amount of serum with high culture efficiency regardless of freshness of blood used. In a method for preparing serum from blood containing at least platelets, a platelet processing step is provided in which platelet membrane in the blood is destroyed. After the platelet processing step, a deposition step for depositing thermolabile protein in blood and a removal step for removing the thermolabile protein, which has been deposited in the deposition step, are preferably provided.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: December 10, 2013
    Assignee: JMS Co., Ltd.
    Inventors: Koji Suzuki, Seishin Tanaka, Satoshi Hirai, Mari Takabatake
  • Publication number: 20130287753
    Abstract: Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies.
    Type: Application
    Filed: June 28, 2013
    Publication date: October 31, 2013
    Inventor: Christopher J. Centeno
  • Patent number: 8529957
    Abstract: The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides compositions comprising plasma or platelet-rich plasma alone or in combination with cell preparations for use in tissue regeneration and bone regeneration and pain reduction.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: September 10, 2013
    Inventors: Antoine Turzi, Donald Francois Du Toit
  • Publication number: 20130129816
    Abstract: A composition that includes nanoparticles with binding affinity for platelets, and methods for using this composition to treat vascular disease are disclosed.
    Type: Application
    Filed: January 9, 2013
    Publication date: May 23, 2013
    Applicant: Abbott Cardiovascular Systems Inc.
    Inventor: Abbott Cardiovascular Systems Inc.
  • Publication number: 20130084341
    Abstract: Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells.
    Type: Application
    Filed: November 26, 2012
    Publication date: April 4, 2013
    Applicant: REGENERATIVE SCIENCES, LLC
    Inventor: Regenerative Sciences, LLC
  • Patent number: 8409810
    Abstract: The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: April 2, 2013
    Assignee: Biogen Idec Ma Inc.
    Inventors: Yen-Ming Hsu, Lihe Su
  • Patent number: 8404256
    Abstract: This invention relates to a process to facilitate osteochondral bone remodeling in a subject by inducing regeneration of this bone to a healthy, vascularized state capable of supporting the underlying hyaline cartilage of articular joints and spinal discs, both biomechanically and metabolically and to deliver a bioactive agent. This process involves the steps of: administering an effective amount of an injectable in situ curing biomaterial composite to a site. The biomaterial composite product is prepared by a process involving the steps: admixing an alginate solution with a nonporous aggregate of ?-tricalcium phosphate, in a sufficient amount to initiate polymerization of the alginate solution, to form a hydrogel having from between 10 to 20 percent by volume of ?-tricalcium phosphate.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: March 26, 2013
    Assignee: The University of Memphis Research Foundation
    Inventors: Jonathan Dempsey McCanless, Warren Ollver Haggard
  • Patent number: 8343518
    Abstract: This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: January 1, 2013
    Assignee: MedImmune, LLC
    Inventor: Vu Truong-Le
  • Publication number: 20120321722
    Abstract: The present invention relates to methods and compositions for reducing sialidase activity and inhibiting bacterial proliferation of one or more bacteria in a platelet product preparation from one or more donors. In general, the method includes contacting the platelet product preparation with an amount of a sialidase inhibitor, to thereby obtain a sialidase inhibitor-treated platelet product preparation. Sialidase activity is reduced and the proliferation of one or more bacteria is inhibited, as compared to a platelet product preparation not subjected to the sialidase inhibitor treatment.
    Type: Application
    Filed: May 17, 2012
    Publication date: December 20, 2012
    Inventors: Qiyong Peter Liu, Karin Hoffmeister
  • Publication number: 20120315338
    Abstract: The present invention provides a method of generating megakaryocytes and platelets. In various embodiments, method involves the use of human embryonic stem cell derived hemangioblasts for differentiation into megakaryocytes and platelets under serum and stromal-free condition. In this system, hESCs are directed towards megakaryocytes through embryoid body formation and hemangioblast differentiation. Further provided is a method of treating a subject in need of platelet transfusion.
    Type: Application
    Filed: December 3, 2010
    Publication date: December 13, 2012
    Applicant: Stem Cell & Regenerative Medicine International, Inc.
    Inventors: Feng Li, Shi-Jiang Lu
  • Publication number: 20120282302
    Abstract: This invention relates to a process to facilitate osteochondral bone remodeling in a subject by inducing regeneration of this bone to a healthy, vascularized state capable of supporting the underlying hyaline cartilage of articular joints and spinal discs, both biomechanically and metabolically and to deliver a bioactive agent. This process involves the steps of: administering an effective amount of an injectable in situ curing biomaterial composite to a site. The biomaterial composite product is prepared by a process involving the steps: admixing an alginate solution with a nonporous aggregate of ?-tricalcium phosphate, in a sufficient amount to initiate polymerization of the alginate solution, to form a hydrogel having from between 10 to 20 percent by volume of ?-tricalcium phosphate.
    Type: Application
    Filed: May 2, 2012
    Publication date: November 8, 2012
    Inventors: Jonathan Dempsey McCanless, Warren Ollver Haggard
  • Patent number: 8303993
    Abstract: The present relates to an autologous bioadhesive sealant composition, or fibrin glue prepared by a two-phase method, wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied. A platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. In one embodiment the platelet rich plasma is divided into two portions. In phase one, a compound that reverses the effect of the anticoagulant is added to the first portion and a clot is allowed to form. The clot is then triturated, and the resulting, serum containing autologous thrombin is collected. In phase two, the serum obtained from phase one is mixed with the second portion of the-platelet rich plasma to form the bioadhesive sealant of the invention.
    Type: Grant
    Filed: June 23, 2005
    Date of Patent: November 6, 2012
    Assignee: Ateriocyte Medical Systems, Inc.
    Inventors: Robert F. Baugh, Lisa M. Lim, Julie S. Johnston, John G. Rivera
  • Patent number: 8282963
    Abstract: This invention provides methods for extracting platelets, compositions obtained therefore, and methods for using the same.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: October 9, 2012
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventor: Mark T. Roedersheimer
  • Patent number: 8268362
    Abstract: The invention relates to a medicinal product for topical use for the promotion of wound healing, which comprises thrombocytes or thrombocyte fragments, wherein the thrombocytes or thrombocyte fragments contain growth factors and are capable of releasing the same and are present in the lyophilized or deep-frozen state and have been subjected to a process for virus partitioning and/or virus inactivation.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: September 18, 2012
    Assignee: Bio-Products & Bio-Engineering Aktiengesellschaft
    Inventors: Friedrich Braun, Hans Peter Spängler, Johann Eibl
  • Publication number: 20120156306
    Abstract: The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.
    Type: Application
    Filed: December 20, 2011
    Publication date: June 21, 2012
    Inventors: Lior Weissman, Nina Raver-Shapira, Israel Nur, Oleg Belyaev
  • Publication number: 20120114761
    Abstract: A skincare stimulant having an effective dose of platelets and pharmaceutically acceptable solvents and/or excipients, wherein the effective dose refers to the presence of at least 1000 platelets in every milligram of skincare stimulant.
    Type: Application
    Filed: November 3, 2011
    Publication date: May 10, 2012
    Applicant: Central Medical Technologies Inc.
    Inventors: Chih I LIN, Han-Lei Wan
  • Patent number: 8168230
    Abstract: A semi-synthetic platelet gel comprising a platelet-rich plasma, at least one platelet activator, and a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof. A method for preparing a semi-synthetic platelet gel comprising the steps of (a) mixing a platelet-rich plasma with at least one platelet activator, and, before the start of clot formation, (b) adding the mixture thus obtained to a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: May 1, 2012
    Assignee: Advance Holdings Limited
    Inventor: Virgilio Evangelista
  • Publication number: 20120093941
    Abstract: Compositions and methods for preparing neutrophil-depleted platelet rich plasma are provided. Generally, these compositions comprise a higher concentration of platelets and depressed concentrations of neutrophils relative to whole blood although white blood cells may be at higher concentrations than whole blood. The concentrations of the platelets and/or the white blood cells may be two to eight times the respective concentrations in whole blood. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The neutrophil-depleted platelet rich plasma composition may be delivered in conjunction with reperfusion therapy.
    Type: Application
    Filed: December 21, 2011
    Publication date: April 19, 2012
    Inventor: Allan Kumar Mishra
  • Patent number: 8137663
    Abstract: A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: March 20, 2012
    Assignee: Wellstat Biologics Corporation
    Inventors: William S. Groene, Jeffrey A. Miller, Stephen N. Mueller
  • Patent number: 8124130
    Abstract: Methods and formulations for the improvement of recovery following bone-impacting injury or surgery. The formulations of the present invention preferably include platelet-rich plasma with a pharmaceutical agent. The pharmaceutical agent may be a glucocorticoid hormone or other organic pharmaceutical agent. Particularly preferred pharmaceutical agents include dexamethasone, melatonin, purmorphamine, 17?-estradiol, vitamin K2 (menaquinone-4, MK4), bisphosphonates, derivatives thereof, and combinations thereof. The formulations of the present invention may be directly administered to a surgical or injury site where improved bone growth is desired. The formulations may also be applied to or otherwise incorporated into scaffolding structural components commonly employed in the medical field to promote bone structure and growth. The pharmaceutical agent may be employed in an immediate release form or a sustained release form.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: February 28, 2012
    Inventor: James Louis Rutkowski
  • Publication number: 20120027867
    Abstract: The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.
    Type: Application
    Filed: April 6, 2010
    Publication date: February 2, 2012
    Applicant: ENTEGRION, INC.
    Inventors: Thomas H. Fischer, Joseph A. DaCorta, Michael Lawrence Galiger
  • Publication number: 20120016489
    Abstract: Implantable pliable bone blocks comprising a solid block of cortical bone characterized by a length, width and thickness, having a first and a second face on opposite sides of the block. The first and second faces have a plurality slot features. The angle of incidence of the slot features of the first face and the x-axis and the angle of incidence of the slot features of the second face and the x-axis (a2) are such that the slots would intersect if they were in the same plane. Methods are provided for making implantable pliable bone blocks.
    Type: Application
    Filed: July 16, 2010
    Publication date: January 19, 2012
    Applicant: EBI, LLC
    Inventor: Bradford J. COALE
  • Patent number: 8067017
    Abstract: This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: November 29, 2011
    Assignee: MedImmune, LLC
    Inventor: Vu Truong-Le
  • Publication number: 20110280952
    Abstract: The present invention concerns the use of platelet lysate for treating and/or preventing mucositis. Moreover, a mucoadhesive composition comprising such a platelet lysate for the therapy and/or prevention of mucositis and of corneal lesions is described.
    Type: Application
    Filed: May 31, 2011
    Publication date: November 17, 2011
    Applicants: BIOMED DEVICE S.R.L., UNIVERSITA' DEGLI STUDI DI PAVIA
    Inventors: Carla Marcella Caramella, Maria Cristina Bonferoni, Silvia Stefania Rossi, Giuseppina Sandri, Franca Ferrari, Cesare Giuseppe Perotti, Claudia Del Fante
  • Publication number: 20110200642
    Abstract: Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells.
    Type: Application
    Filed: December 18, 2008
    Publication date: August 18, 2011
    Applicant: REGENERATIVE SCIENCES, LLC
    Inventor: Christopher J. Centeno
  • Patent number: 7901344
    Abstract: A method of treating irradiated tissue, such as for revascularizing and preventing or reducing wound healing complications in a human or other animal subject having cancer. The method comprises administering to the irradiated tissue a therapeutic composition comprising one or more of platelet rich plasma, platelet poor plasma or platelet concentrate. In some embodiments the complications sought to be prevented and/or reduced can include: fibrotic tissue, prolonged would drainage, hematomas, seromas, fistula formation infection, pain, poor coloration, deficient vascularity, and desensitization in or around the irradiated site.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: March 8, 2011
    Assignee: Biomet Biologics, LLC
    Inventor: John Yoo
  • Publication number: 20110052533
    Abstract: Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies.
    Type: Application
    Filed: March 13, 2009
    Publication date: March 3, 2011
    Applicant: REGENERATIVE SCIENCES, LLC
    Inventor: Christopher J. Centeno
  • Publication number: 20110027338
    Abstract: The invention provides composition and methods for repairing a ruptured anterior cruciate ligament.
    Type: Application
    Filed: October 7, 2010
    Publication date: February 3, 2011
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Martha M. Murray, Michael F. Murray, Jennifer Marler